Lead Product(s) : Torsemide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Novo Integrated Sciences
Deal Size : Undisclosed
Deal Type : Agreement
Details : Sarfez’s FDA-approved, once-a-day novel formulation of loop diuretic torsemide, SOAANZ®, provides a new treatment option for patients suffering from heart failure who experience persistent edema or swelling in the lower limbs and/or abdomen.
Product Name : Soaanz
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 30, 2022
Lead Product(s) : Torsemide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Novo Integrated Sciences
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
